Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 17828307 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Wu L, et al. (2008) Distinct FAK-Src activation events promote alpha5beta1 and alpha4beta1 integrin-stimulated neuroblastoma cell motility. Oncogene 27, 1439-48 17828307
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

Y397-p - FAK (human)
Orthologous residues
FAK (human): Y397‑p, FAK iso2 (human): Y216‑p, FAK iso5 (human): Y397‑p, FAK (mouse): Y428‑p, FAK iso3 (mouse): Y397‑p, FAK iso4 (mouse): Y397‑p, FAK (rat): Y397‑p, FAK (chicken): Y397‑p, FAK iso5 (chicken):
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, neuroblastoma
 Relevant cell lines - cell types - tissues:  MEF (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
 Comments:  NB8 cells
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE FAK (human)
KINASE Src (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FAK (human) decrease dominant negative (FRNK domain), plated on fibronectin (9-11)
FAK (human) no change compared to control dominant negative (FRNK domain), plated on fibronectin (CS-1)
PP2 no change compared to control plated on fibronectin (CS-1)
PP3 no change compared to control plated on fibronectin (CS-1)

Y419-p - Src (human)
Orthologous residues
Src (human): Y419‑p, Src (mouse): Y424‑p, Src iso2 (mouse): Y418‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, neuroblastoma
 Relevant cell lines - cell types - tissues:  MEF (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
 Comments:  NB8 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PP2 decrease
PP3 no change compared to control
FAK (human) no change compared to control dominant negative (FRNK domain)
siRNA FAK (human) decrease
ITGA4 (human) decrease null

Y530-p - Src (human)
Orthologous residues
Src (human): Y530‑p, Src (mouse): Y535‑p, Src iso2 (mouse): Y529‑p, Src (rat): Y530‑p, Src (chicken): Y527‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  brain cancer, neuroblastoma
 Relevant cell lines - cell types - tissues:  MEF (fibroblast)
 Cellular systems studied:  cell lines
 Species studied:  human, mouse
 Comments:  NB8 cells
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PTPRA (human) increase catalytically inactive
PTPRA (human) no change compared to control

Y424-p - Src (mouse)
Orthologous residues
Src (human): Y419‑p, Src (mouse): Y424‑p, Src iso2 (mouse): Y418‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
fibronectin increase CS-1
fibronectin PTPRA (human) augment treatment-induced increase

Y535-p - Src (mouse)
Orthologous residues
Src (human): Y530‑p, Src (mouse): Y535‑p, Src iso2 (mouse): Y529‑p, Src (rat): Y530‑p, Src (chicken): Y527‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PTPRA (human) decrease


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.